Skip to main content

Table 3 Prognostic impact of miR-124 methylation levels and haematological factors in patients with MDS

From: Pyrosequencing quantified methylation level of miR-124 predicts shorter survival for patients with myelodysplastic syndrome

Variables Overall survival (OS) Leukaemia-free survival (LFS)
No. of No. of Univariate Multivariate No. of Univariate Multivariate
patients event P P event P P
Sex    0.326   0.513
 Male 36 20    9   
 Female 20 14    6   
Age    0.103   0.023 0.002
  < 60 25 12    3   
  ≥ 60 31 22    12   
WBC (× 109/L)    0.932   0.313
  ≥ 4 13 8    2   
  < 4 43 26    13   
Hb(g/dL)    0.058   0.050
  ≥ 10 9 4    0   
  < 10 47 30    15   
PLT (× 109/L)    0.469   0.702
  ≥ 100 18 9    4   
  < 100 38 25    11   
MCV(fL)    0.014 0.111   0.861
  ≥ 100 28 13    8   
  < 100 28 21    7   
WHO classification    <0.001 0.016   0.003 0.944
 SLD/RS-SLD/
MDS-U/5q-
10 5    0   
 MLD/RS-MLD 10 2    0   
 EB-1/EB-2 36 27    15   
BM blast (%)    <0.001 0.003   <0.001 0.453
  < 5 20 7    0   
 5–10 15 10    3   
 11–19 21 17    12   
Cytopenias    0.391   0.19
 0/1 11 5    1   
 2/3 45 29    14   
Karyotype    0.005 <0.001   0.626
 Good 34 18    9   
 Intermediate 7 5    2   
 Poor 14 11    4   
IPSS    0.002 0.007   0.004 0.122
 Low 4 1    0   
 Int-1 24 12    2   
 Int-2 19 14    10   
 High 8 7    3   
miR-124-1 methylation    0.025 0.810   0.029 0.125
 Low 33a,43b 17    9   
 High 23 a,13b 17    6   
miR-124-2 methylation    0.004 0.312   0.001 0.307
 Low 27 13    2   
 High 29 21    13   
miR-124-3 methylation    0.010 0.028   0.069 -
 Low 21 10    3   
 High 35 24    12   
  1. Different cut-off values of methylation levels were used to predict OS and LFS (Tables 1 and 2); therefore, ameans the number of patients with low or high methylation levels to predict OS, and bmeans the number of patients with low or high methylation levels to predict LFS
  2. Italics are statistically significant